Condition
Prostatic Hyperplasia
Urology / Fertility
Overview
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
This information is general and should not be treated as medical advice. Always speak directly with a qualified healthcare professional before making decisions about treatment, diagnosis, procedures, medicines or care.
Quick facts about Prostatic Hyperplasia
- Topic type
- Condition
- Category
- Urology / Fertility
- MeSH classification
- C12.100.500.565.500|C12.200.294.565.500
Preparing for an appointment about Prostatic Hyperplasia
If you are speaking with a healthcare professional about Prostatic Hyperplasia, it can help to prepare a few details in advance.
- Write down your symptoms and when they started.
- Bring details of any medicines, supplements or previous treatments.
- Ask what tests or assessments may be needed.
- Ask what treatment or management options may be suitable.
- Ask when you should seek urgent medical help or follow-up care.
Finding care related to Prostatic Hyperplasia
EuroCareFinder helps patients explore clinics and healthcare providers across Europe. Some topics link directly to services offered by clinics, while others may be connected through related specialties, treatments or procedures.
Explore clinics across Europe
Browse the wider EuroCareFinder healthcare network using the interactive map.
Clinics related to Prostatic Hyperplasia
No clinics are currently linked directly to Prostatic Hyperplasia on EuroCareFinder.
As more clinics add detailed services, related providers may appear here.
Related topics
Explore healthcare providers
Use EuroCareFinder to browse clinics by country, specialty and available services.
Source: Medical Subject Headings (MeSH), produced by the U.S. National Library of Medicine. EuroCareFinder is not endorsed by the National Library of Medicine. MeSH version: 2026.